Payment overview · 2025
General Payments
$1,230.20
48 reported records · 18 companies
Healthcare provider profile · identity verified
Netsanet Tefera, NP
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Adult Health · PLANO, TX · NPI 1154973147
Verified facts
What the public records show
CMS Open Payments records show Netsanet Tefera, NP received $1,230.20 in general payments during 2025 across 48 reported records.
Amgen Inc. accounted for 17.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 30 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Gemtesa, Ozempic, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Synthroid by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 54 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 72 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 58 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 40 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Paxlovid by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GEMTESA as an associated drug or biological on 61692 records involving 22152 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Gemtesa by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Amgen Inc. | Unresolved — no canonical attribution shown | $211.53 | 17.2% | 6 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $185.76 | 15.1% | 3 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $75.92 | 6.2% | 3 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $73.20 | 6.0% | 4 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$72.06 | 5.9% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $71.66 | 5.8% | 4 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $69.98 | 5.7% | 3 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $66.28 | 5.4% | 3 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $59.92 | 4.9% | 3 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $58.51 | 4.8% | 3 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $56.12 | 4.6% | 3 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $56.10 | 4.6% | 3 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $52.67 | 4.3% | 2 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $32.25 | 2.6% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $32.21 | 2.6% | 2 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $20.29 | 1.6% | 1 | 2025 |
| Dynavax Technologies Corporation | Unresolved — no canonical attribution shown | $18.44 | 1.5% | 1 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $17.30 | 1.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,230.20 | 48 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $201.97 | 5 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $121.82 | 1 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $69.98 | 3 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $66.28 | 3 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $63.94 | 2 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $59.92 | 3 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $58.51 | 3 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $56.12 | 3 | 2025 |
Source payment records
|
|||||
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $56.10 | 3 | 2025 |
Source payment records
|
|||||
| KYPHON EXPRESS II KYPHOPAK TRAY Normalized: kyphon express ii kyphopak tray |
Device | Medtronic, Inc. | $55.78 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $52.67 | 2 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $52.67 | 2 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $52.67 | 2 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $51.57 | 3 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $50.20 | 1 | 2025 |
Source payment records
|
|||||
| OFEV Normalized: ofev |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $49.61 | 2 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $38.77 | 2 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $34.43 | 2 | 2025 |
Source payment records
|
|||||
| Leqembi Normalized: leqembi |
Drug | Eisai Inc. | $32.25 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $32.21 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $31.29 | 2 | 2025 |
Source payment records
|
|||||
| JASCAYD Normalized: jascayd |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $26.31 | 1 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $22.84 | 2 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $22.21 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $20.29 | 1 | 2025 |
Source payment records
|
|||||
| Heplisav-B Normalized: heplisav b |
Drug | Dynavax Technologies Corporation | $18.44 | 1 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $17.30 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $16.75 | 1 | 2025 |
Source payment records
|
|||||
| INTELLIS ADAPTIVESTIM Normalized: intellis adaptivestim |
Device | Medtronic, Inc. | $16.28 | 1 | 2025 |
Source payment records
|
|||||
| KRYSTEXXA Normalized: krystexxa |
Biological | Amgen Inc. | $9.56 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 17 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| GEMTESA gemtesa |
2025 | Gemtesa | 2024 | 16 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 72 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 23 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
33 | 11 |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
54 | 17 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
72 | 14 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
58 | 15 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
40 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
13 | 13 |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | GEMTESA open payments reported associated product |
CMS Open Payments — General Payments 61692 supporting records · 22152 recipient NPIs · example record 1176593503 |
Gemtesa · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 280 | 101 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 221 | 80 |
| Atorvastatin Calcium | Atorvastatin Calcium | 209 | 74 |
| Losartan Potassium | Losartan Potassium | 206 | 73 |
| Amlodipine Besylate | Amlodipine Besylate | 135 | 53 |
| Montelukast Sodium | Montelukast Sodium | 116 | 39 |
| Trazodone Hcl | Trazodone Hcl | 116 | 50 |
| Gabapentin | Gabapentin | 101 | 47 |
| Lisinopril | Lisinopril | 100 | 40 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 78 | 33 |
| Escitalopram Oxalate | Escitalopram Oxalate | 74 | 29 |
| Ozempic | Semaglutide | 72 | 14 |
| Pantoprazole Sodium | Pantoprazole Sodium | 72 | 28 |
| Duloxetine Hcl | Duloxetine Hcl | 71 | 30 |
| Sertraline Hcl | Sertraline Hcl | 71 | 30 |
| Metformin Hcl | Metformin Hcl | 70 | 22 |
| Glimepiride | Glimepiride | 69 | 24 |
| Metoprolol Succinate | Metoprolol Succinate | 68 | 27 |
| Azelastine Hcl | Azelastine Hcl | 65 | 35 |
| Simvastatin | Simvastatin | 65 | 25 |
| Prednisone | Prednisone | 64 | 55 |
| Omeprazole | Omeprazole | 63 | 24 |
| Furosemide | Furosemide | 60 | 24 |
| Hydrochlorothiazide | Hydrochlorothiazide | 59 | 22 |
| Meloxicam | Meloxicam | 59 | 28 |
| Alendronate Sodium | Alendronate Sodium | 58 | 16 |
| Rybelsus | Semaglutide | 58 | 15 |
| Metformin Hcl Er | Metformin Hcl | 57 | 28 |
| Ezetimibe | Ezetimibe | 56 | 23 |
| Jardiance | Empagliflozin | 54 | 17 |
| Potassium Chloride | Potassium Chloride | 46 | 18 |
| Fluticasone Propionate | Fluticasone Propionate | 45 | 16 |
| Pravastatin Sodium | Pravastatin Sodium | 42 | 14 |
| Azithromycin | Azithromycin | 40 | 38 |
| Eliquis | Apixaban | 40 | suppressed |
| Mirtazapine | Mirtazapine | 39 | 13 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 36 | 13 |
| Zolpidem Tartrate | Zolpidem Tartrate | 36 | 11 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 34 | 31 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 33 | 12 |
| Synthroid | Levothyroxine Sodium | 33 | 11 |
| Fluoxetine Hcl | Fluoxetine Hcl | 32 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 32 | 14 |
| Citalopram Hbr | Citalopram Hydrobromide | 31 | 14 |
| Carvedilol | Carvedilol | 29 | 13 |
| Hydralazine Hcl | Hydralazine Hcl | 29 | 17 |
| Metoprolol Tartrate | Metoprolol Tartrate | 29 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 28 | 12 |
| Tizanidine Hcl | Tizanidine Hcl | 27 | 17 |
| Clopidogrel | Clopidogrel Bisulfate | 26 | 11 |
| Estradiol | Estradiol | 26 | 13 |
| Allopurinol | Allopurinol | 25 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 24 | 13 |
| Januvia | Sitagliptin Phosphate | 24 | suppressed |
| Pregabalin | Pregabalin | 24 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 23 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 22 | 12 |
| Donepezil Hcl | Donepezil Hcl | 22 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 22 | 14 |
| Bupropion Xl | Bupropion Hcl | 21 | suppressed |
| Mupirocin | Mupirocin | 21 | 15 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 21 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 20 | 15 |
| Famotidine | Famotidine | 20 | 13 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 19 | 18 |
| Tamsulosin Hcl | Tamsulosin Hcl | 19 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 18 | 17 |
| Nifedipine Er | Nifedipine | 18 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 17 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 17 | suppressed |
| Memantine Hcl | Memantine Hcl | 17 | suppressed |
| Methylprednisolone | Methylprednisolone | 17 | 17 |
| Mounjaro | Tirzepatide | 17 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 17 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 16 | suppressed |
| Gemtesa | Vibegron | 16 | suppressed |
| Myrbetriq | Mirabegron | 15 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 14 | 14 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 14 | suppressed |
| Estradiol (Twice Weekly) | Estradiol | 14 | suppressed |
| Etodolac | Etodolac | 14 | 12 |
| Glipizide Er | Glipizide | 14 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 14 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 14 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 13 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 13 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 13 | 13 |
| Propranolol Hcl | Propranolol Hcl | 13 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 13 | suppressed |
| Valsartan | Valsartan | 13 | suppressed |
| Acyclovir | Acyclovir | 12 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 12 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 12 | suppressed |
| Ramipril | Ramipril | 12 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 11 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 11 | suppressed |
| Finasteride | Finasteride | 11 | suppressed |
| Methocarbamol | Methocarbamol | 11 | suppressed |
| Ondansetron Odt | Ondansetron | 11 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 11 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,230.20 · 48 records | Amgen Inc. | ABRYSVO, AIRSUPRA, AREXVY, BREZTRI, COMIRNATY, Cologuard Collection Kit, Dexcom G6 Transmitter, EVENITY, FARXIGA, FREESTYLE LIBRE 3, GEMTESA, Heplisav-B, INTELLIS ADAPTIVESTIM, JASCAYD, KRYSTEXXA, KYPHON EXPRESS II KYPHOPAK TRAY, Kerendia, Leqembi, OFEV, Ozempic, PREVNAR 20, PROLIA, QULIPTA, SHINGRIX, TRELEGY ELLIPTA, TZIELD, UBRELVY, Veozah, Wegovy, YUPELRI | 10 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error